Page 216 - The Vasculitides Volumes 2

192 Kelly G. Gwathmey, Jennifer A. Tracy and P. James B. Dyck

[106] Smith, R. M., Jones, R. B., Jayne, D. R. Progress in treatment of ANCA-associated
vasculitis. Arthritis Res. Ther. 2012; 14:210.

[107] Stasi, R., Stipa, E., Del Poeta, G., et al. Long-term observation of patients with anti-
neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Rheumatology 2006; 45:1432-1436.

[108] Dyck, P. J. B., Engelstad, J., Norell, J., et al. Microvasculitis in non-diabetic
lumbosacral radiculoplexus neuropathy (LSRPN): similarity to the diabetic variety
(DLSRPN). J. Neuropathol. Exp. Neurol. 2000; 59:525-538.

[109] Gorson, K. C. Therapy for vasculitic neuropathies. Curr. Treat. Options Neurol. 2006;
8:105-117.

[110] Tervaert, J. W., Limburg, P. C., Elema, J. D., et al. Detection of autoantibodies against
myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-
proven necrotizing arteritis. Am. J. Med. 1991;91:59-66.

[111] Gayraud, M., Guillevin, L., Cohen, P., et al. Treatment of good-prognosis polyarteritis
nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse
cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides.
Brit. J. Rheumatol. 1997; 36:1290-1297.

[112] De Groot, K., Harper, L., Jayne, D. R. W., et al. Pulse versus daily oral
cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-
associated vasculitis: a randomized trial. Ann. Intern. Med. 2009; 150:670-680.

[113] Haubitz, M., Schellong, S., Göbel, U., et al. Intravenous pulse administration of
cyclophosphamide versus daily oral treatment in patients with antineutrophil
cytoplasmic antibody-associated vasculitis and renal involvement: a prospective,
randomized study. Arthritis Rheum. 1998; 41:1835-1844.

[114] Guillevin, L., Cordier, J. F., Lhote, F., et al. A prospective, multicenter, randomized
trial comparing steroids and pulse cyclophosphamide versus steroids and oral
cyclophosphamide in the treatment of generalized Wegener?s granulomatosis. Arthritis
Rheum. 1997; 40:2187-2198.

[115] Adu, D., Pall, A., Luqmani, R. A., et al. Controlled trial of pulse versus continuous
prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;
90:401-409.

[116] Harper, L., Morgan, M. D., Walsh, M., et al. Pulse versus daily oral cyclophosphamide
for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann.
Rheum. Dis. 2012; 71:955-960.

[117] Jayne, D., Rasmussen, N., Andrassy, K., et al. A randomized trial of maintenance
therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N.
Eng. J. Med. 2003; 349:36-44.

[118] Gold, R., Fontana, A., Zierz, S. Therapy of neurological disorders in systemic
vasculitis. Semin. Neurol. 2003; 23:207-214.

[119] Langford, C. A. 15. Vasculitis. J. Allergy Clin. Immunol. 2003; 111:S602-612.
[120] Hellmich, B., Flossmann, O., Gross, W. L., et al. EULAR recommendations for

conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-
neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 2007; 66:605-
617.
[121] Jones, R. B., Tervaert, J. W. C., Hauser, T., et al. Rituximab versus cyclophosphamide
in ANCA-associated renal vasculitis. N. Engl. J. Med. 2010; 363:211-220.

Complimentary Contributor Copy